Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Fractyl Health, Inc. - Common Stock (NQ:GUTS)

1.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fractyl Health, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Monday?
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
From Fractyl Health, Inc.
Via GlobeNewswire
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Earnings Scheduled For March 3, 2025
 
Via Benzinga
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
From Fractyl Health, Inc.
Via GlobeNewswire
What's going on in today's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Participate in the Upcoming December Conferences
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.